Fig. 1From: Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regressionForest plot of risk (HR, hazard ratio) of MACE (major cardiovascular events) with the use of DPP-4i, GLP-1RA or SGLT-2i, as compared with placebo, in patients with type 2 diabetes participating in 18 CVOTs (cardiovascular outcome trials)Back to article page